TG Therapeutics, Inc. (NASDAQ: TGTX) Q2 2025 Earnings | 08/04/2025

18 days ago

28:53

Inside Ticker

Earnings Calls

AI Summary

Summary of TG Therapeutics Q2 2025 Earnings Call

Key Highlights:

Strong Financial Performance: TG Therapeutics reported $141.1M in total revenue for Q2 2025, including $138.8M in U.S. net product revenue from BRIUMVI® (ublituximab), marking 91% YoY growth.
Increased Guidance: The company raised its full-year 2025 BRIUMVI revenue guidance to $570–575M (up from $560M), citing strong new patient starts and high persistence rates.
Market Share Growth: BRIUMVI now captures ~1 in 3 new IV anti-CD20 MS patients, reinforcing its competitive position in the $8B+ U.S. MS CD20 market.
Subcutaneous BRIUMVI Development: Enrollment for the pivotal Phase 3 trial will begin soon, evaluating every-other-month and quarterly dosing vs. IV. Target timelines:
- Enrollment completion: 2026
- BLA submission: 2027
- Potential launch: 2028
IV Dosing Optimization: A Phase 3 trial is underway to evaluate consolidating the Day 1 & Day 15 infusions into a single 600mg infusion, with data expected in 2026.
Pipeline Updates:
- First patient dosed in a progressive MS trial for AZER-CEL (CD19 CAR-T therapy).
- Exploring BRIUMVI in myasthenia gravis.
Commercial Momentum:
- Highest quarterly new patient enrollments since launch.
- National TV campaign driving brand awareness, with increased patient requests for BRIUMVI by name.
- Strong performance in hospital and VA settings.
Financials:
- GAAP net income of $28.2M ($0.17/share) vs. $6.9M in Q2 2024.
- Cash position: $279M, supporting ongoing R&D and commercialization.

Outlook:
TG Therapeutics remains confident in BRIUMVI’s growth trajectory, with plans to expand into subcutaneous delivery and new indications, positioning the company for long-term leadership in MS and neuroimmunology.

About this video

TG Therapeutics, Inc. delivered a robust second quarter for 2025, with total revenue soaring 92% year-over-year to $141.1 million, including $138.8 million in U.S. net product revenue—primarily from its lead therapy, BRIUMVI, for relapsing multiple sclerosis. License, milestone, and royalty revenue more than doubled to $2.3 million. Gross margin remained strong at 87.4%. GAAP net income jumped to $28.2 million ($0.17 per diluted share), rising from $6.9 million ($0.04 per share) in Q2 2024, though EPS missed consensus forecasts due to elevated operating expenses, including increased R&D and SG&A for pipeline progress and commercial investment. Operating expenses totaled $71 million, up from $46.9 million in the prior year but down sequentially, mainly reflecting BRIUMVI’s continued launch, development of a subcutaneous formulation, and new studies in myasthenia gravis and progressive MS. Despite heavier costs, revenue outpaced expenses, supporting both profitability and a positive earnings trajectory. Driven by strong BRIUMVI uptake (91% YoY and 16% QoQ growth), management raised full-year 2025 U.S. net revenue guidance to $570–$575 million (global ~$585 million), up from its previous forecast. The company ended the quarter with $278.9 million in cash, cash equivalents, and investments, ensuring financial flexibility for continued commercial expansion and R&D initiatives. Strategically, TG Therapeutics is advancing ENHANCE (consolidated dosing) and expanding its portfolio to additional indications, while also preparing a direct-to-consumer campaign to further boost BRIUMVI adoption in the U.S. and leveraging partnership-driven launches in Europe. About Inside Ticker: For more expert analysis and real-time updates on TG Therapeutics, Inc. (NASDAQ: TGTX) and other market movers, follow Inside Ticker and visit http://www.insideticker.com/ for in-depth reports, financial insights, and the latest news on leading companies. #TGTherapeutics #TGTX #Q22025 #Earnings #FinancialResults #RevenueGrowth #NetIncome #EPS #BRIUMVI #MultipleSclerosis #Pipeline #Guidance #Profitability #CashFlow #Commercialization #InsideTicker #2025Outlook

Important Note: The stock market is inherently unpredictable, and forecasts are subject to change based on various factors, including economic conditions and company performance. Always consult multiple sources and consider professional advice before making investment decisions.

AI-Powered Financial Analysis This analysis uses real-time market data. While we strive for accuracy, always verify important financial information and consult with qualified financial professionals before making investment decisions. Past performance does not guarantee future results.